Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Isofol Medical AB ( (SE:ISOFOL) ).
Isofol Medical AB has commenced a clinical phase Ib/II study of its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the benefit/risk profile and efficacy of arfolitixorin in a new dosing regimen. This milestone marks a significant step in Isofol’s plan to bring arfolitixorin closer to market, potentially offering improved treatment options for patients with advanced cancers.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of first-line standard treatments for several solid tumors, with a current focus on colorectal cancer. Isofol Medical AB is listed on Nasdaq Stockholm.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue